All entries for: Xenon Pharmaceuticals

February 26, 2026

Xenon Pharmaceuticals

Neutral Outlook

Canada
201-500 employees

In May 2025, another Executive Order was issued that directed government agencies and officials to identify most-favored nation pricing targets for prescription drugs (and looked to pharmaceutical manufacturers to make significant progress towards delivering target prices to patients), prevent foreign countries from disproportionately shifting the cost of global pharmaceutical research and development to the United States, and facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers to sell their products to patients at the most-favored-nation price.

February 26, 2026

Xenon Pharmaceuticals

Neutral Outlook

Canada
201-500 employees

The IRA has had and will likely continue to have a significant impact on the pharmaceutical industry.

Disease Area: Neurological Diseases, Psychiatry
Drug Type: Small Molecule
November 3, 2025

Xenon Pharmaceuticals

Negative Outlook

Canada
201-500 employees

As another example, in May 2025, an Executive Order was issued that directed government agencies and officials to identify most-favored-nation pricing targets for prescription drugs (and looked to pharmaceutical manufacturers to make significant progress towards delivering target prices to patients), prevent foreign countries from disproportionately shifting the cost of global pharmaceutical research and development to the United States, and facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers to sell their products to patients at the most-favored-nation price.

August 11, 2025

Xenon Pharmaceuticals

Neutral Outlook

Canada
201-500 employees

As another example, in May 2025, an Executive Order was issued that directed government agencies and officials to identify most-favored-nation pricing targets for prescription drugs (and looked to pharmaceutical manufacturers to make significant progress towards delivering target prices to patients), prevent foreign countries from disproportionately shifting the cost of global pharmaceutical research and development to the United States, and facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers to sell their products to patients at the most-favored-nation price. Many of these reform initiatives will require additional legal and/or administrative action to implement.

Scroll to Top